PURPOSE: This study determined the range of tolerable doses, clinical safety, pharmacokinetics, and preliminary evidence of clinical activity following once or twice daily administration of lapatinib in patients with solid malignancies. EXPERIMENTAL DESIGN: Cancer patients (n = 81) received oral doses of lapatinib ranging from 175 to 1,800 mg once daily or 500 to 900 mg twice daily. Clinical assessments of safety and antitumor activity were recorded and blood was sampled for pharmacokinetic assessments. The effect of a low-fat meal on lapatinib pharmacokinetics was assessed in a subset of patients. RESULTS: Lapatinib was well tolerated, such that dose escalation was limited at 1,800 mg once daily only by pill burden. Twice-daily dosing was implemented to further explore tolerability, and was limited by diarrhea to 500 mg twice daily. The most commonly reported adverse events with once-daily dosing were diarrhea (48%), nausea (40%), rash (40%), and fatigue (38%) and with twice-daily dosing were diarrhea (85%), rash (54%), and nausea (34%). Lapatinib serum concentrations accumulated upon repeated dosing, increasing nearly in proportion with dose, and were significantly increased when dosed with food or administered twice daily. One patient with head and neck cancer achieved a confirmed complete response and 22 patients had stable disease of >or=8 weeks including three patients with stable disease of >10 months (renal, lung, and salivary gland cancers). CONCLUSION: Lapatinib was well tolerated following once and twice daily administration. Systemic exposure to lapatinib was dependent on the dose, duration and frequency of dosing, and prandial state. Clinical activity was observed.
PURPOSE: This study determined the range of tolerable doses, clinical safety, pharmacokinetics, and preliminary evidence of clinical activity following once or twice daily administration of lapatinib in patients with solid malignancies. EXPERIMENTAL DESIGN:Cancerpatients (n = 81) received oral doses of lapatinib ranging from 175 to 1,800 mg once daily or 500 to 900 mg twice daily. Clinical assessments of safety and antitumor activity were recorded and blood was sampled for pharmacokinetic assessments. The effect of a low-fat meal on lapatinib pharmacokinetics was assessed in a subset of patients. RESULTS:Lapatinib was well tolerated, such that dose escalation was limited at 1,800 mg once daily only by pill burden. Twice-daily dosing was implemented to further explore tolerability, and was limited by diarrhea to 500 mg twice daily. The most commonly reported adverse events with once-daily dosing were diarrhea (48%), nausea (40%), rash (40%), and fatigue (38%) and with twice-daily dosing were diarrhea (85%), rash (54%), and nausea (34%). Lapatinib serum concentrations accumulated upon repeated dosing, increasing nearly in proportion with dose, and were significantly increased when dosed with food or administered twice daily. One patient with head and neck cancer achieved a confirmed complete response and 22 patients had stable disease of >or=8 weeks including three patients with stable disease of >10 months (renal, lung, and salivary gland cancers). CONCLUSION:Lapatinib was well tolerated following once and twice daily administration. Systemic exposure to lapatinib was dependent on the dose, duration and frequency of dosing, and prandial state. Clinical activity was observed.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: J Baselga; D Pfister; M R Cooper; R Cohen; B Burtness; M Bos; G D'Andrea; A Seidman; L Norton; K Gunnett; J Falcey; V Anderson; H Waksal; J Mendelsohn Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Henry L Gomez; Dinesh C Doval; Miguel A Chavez; Peter C-S Ang; Zeba Aziz; Shona Nag; Christina Ng; Sandra X Franco; Louis W C Chow; Michael C Arbushites; Michelle A Casey; Mark S Berger; Steven H Stein; George W Sledge Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544
Authors: Kevin M Koch; Nandi J Reddy; Roger B Cohen; Nancy L Lewis; Bonnie Whitehead; Kathleen Mackay; Andrew Stead; Andrew P Beelen; Lionel D Lewis Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544
Authors: Edith A Perez; Maria Koehler; Julie Byrne; Alaknanda J Preston; Erica Rappold; Michael S Ewer Journal: Mayo Clin Proc Date: 2008-06 Impact factor: 7.616
Authors: Joseph W Polli; Joan E Humphreys; Kelly A Harmon; Stephen Castellino; Michael J O'Mara; Katie L Olson; Lisa St John-Williams; Kevin M Koch; Cosette J Serabjit-Singh Journal: Drug Metab Dispos Date: 2008-01-23 Impact factor: 3.922
Authors: Wenle Xia; Robert J Mullin; Barry R Keith; Lei-Hua Liu; Hong Ma; David W Rusnak; Gary Owens; Krystal J Alligood; Neil L Spector Journal: Oncogene Date: 2002-09-12 Impact factor: 9.867
Authors: Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart Journal: Clin Pharmacokinet Date: 2016-03 Impact factor: 6.447
Authors: Nathan G Dolloff; Patrick A Mayes; Lori S Hart; David T Dicker; Robin Humphreys; Wafik S El-Deiry Journal: Sci Transl Med Date: 2011-06-08 Impact factor: 17.956
Authors: Jonas A de Souza; Darren W Davis; Yujian Zhang; Arun Khattri; Tanguy Y Seiwert; Serdal Aktolga; Stuart J Wong; Mark F Kozloff; Sreenivasa Nattam; Mark W Lingen; Rangesh Kunnavakkam; Kerstin M Stenson; Elizabeth A Blair; Jeffrey Bozeman; Janet E Dancey; Everett E Vokes; Ezra E W Cohen Journal: Clin Cancer Res Date: 2012-02-27 Impact factor: 12.531
Authors: Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Clin Pharmacokinet Date: 2014-04 Impact factor: 6.447